BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses

Summary: High-risk non-muscle-invasive bladder cancer (NMIBC) is treated with intravesical instillations of Bacillus Calmette-Guérin (BCG), which trigger a local immune response. Improved patient outcomes have been linked to the recruitment of CD4+ T helper type 1 (Th1) cells to the bladder. However...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Paul Rollin, Benjamin Pluskwa, Emilie Artru, Tristan Le Vaslot, Daria Kartasheva-Ebertz, Diane Biron, Margaux Bossis, Fanny Onodi, Joel LeMaoult, Nathalie Rouas-Freiss, Mathieu F. Chevalier, Cecilia S. Lindestam Arlehamn, Alessandro Sette, Alexandra Masson-Lecomte, François Desgrandchamps, Evanguelos Xylinas, Pierre Tonnerre
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-02-01
Edice:	iScience
Témata:	immunology oncology therapeutics immune response
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589004226000519
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!